Ask Dr. Nandi: FDA wants two months of safety data before considering COVID-19 vaccine
3 years ago
156
There are new FDA guidelines for coronavirus vaccine developers. Two months of follow-up data on volunteers in phase 3 trials are now needed before Emergency Use Authorization will be considered.
Loading comments...
-
0:35
WXYZ
7 months agoAccess Hollywood coming to WXYZ on Sept. 11
6151 -
2:14
WFTX
3 years agoCOVID-19 vaccine not possible before election
428 -
1:06
Just the News
3 years agoWHO: COVID-19 Vaccine Safety Comes 'First and Foremost'
44.2K -
2:09
Newsy
3 years agoFDA Will Consider OK'ing COVID-19 Vaccine Before End Of Phase 3 Trials
564 -
0:46
KTNV
3 years agoCOVID-19 vaccine accessibility
9302 -
0:18
KTNV
3 years agoCOVID-19 vaccine alternatives
3.96K6 -
1:37
WXYZ
3 years agoCOVID-19 Vaccine Trial
4.71K2 -
0:44
Newsy
3 years agoEarly Data From Novavax COVID-19 Vaccine Shows Promise
1.9K1 -
1:03
Newsy
3 years agoFDA May Authorize Vaccine Before Trials Finish
1.72K -
0:41
KERO
3 years agoRussia registers COVID-19 vaccine
5.18K2
